IL15 and acute myeloid leukemia: Importantly, when mice who had cleared the initial AML graft were rechallenged with tumor cells after 40 days, while in the presence of daily IL-15 administration, CAR T-cells demonstrated ongoing persistence and cytotoxicity [95].